



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bentzien, J. et al) Art Unit: To be assigned
U.S. Appln. No. : 10/632,888) Examiner: To be assigned
Confirmation No. : To be assigned
U.S. Filing Date : August 1, 2003
Title of Invention : Substituted Benzimidazole Compounds
Attny. Docket No. : 9/254

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

September 26, 2003

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow.

☒ 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

☐ A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No.

☐ 1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).

☐ 1.97(e).

☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or

☐ No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,



Anthony P. Bottino
Attorney for Applicant(s)
Reg. No. 41,629


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 791-6764
Date: September 26, 2003

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on September 26, 2003.



Anthony P. Bottino, Reg. No. 41,629



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		C m p l e t e i f K n w n			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/632,888		
		Filing Date	August 1, 2003		
		First Named Inventor	Bentzien, J. et al		
		Art Unit	to be assigned		
		Examiner Name	to be assigned		
Sheet	1	of	2	Attorney Docket Number	9/254

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		us- 4,139,626	02/13/1979	Beard, C.	
		us- 4,191,764	03/04/1980	Beard, C.	
		us- 4,312,873	01/26/1982	Beard, C.	
		us- 5,141,950	08/25/1992	Nakane, M. et al	
		us- 5,180,724	01/19/1993	Bowles, S. et al	
		us- 5,270,148	12/14/1993	Morigaki, M. et al	
		us- 5,541,339	07/30/1996	Kelly, R. et al	
		us- 5,559,127	09/24/1996	Hartman, G. et al	
		us- 5,616,537	04/01/1997	Yokota, S. et al	
		us- 5,770,544	06/23/1998	Yokota, S. et al	
		us- 2003/0144286	07/31/2003	Frenkel, A. et al	
		us- 2003/0125550	07/03/2003	Blume, T. et al	
		us-			
		us-			
		us-			
		us-			
		us-			
		us-			
		us-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 01/70705 A1	09/27/2001	Alcon Universal Ltd.		
		WO 01/21634 A1	03/29/2001	Trega Biosciences		
		CA 1094061	01/20/1981	Syntex, Inc.		
		CA 2115737	08/17/1994	Dr. Karl Thomae		
		WO 01/25238	04/12/2001	Boehringer Ingelheim Pharmaceuticals, Inc		
		WO99/24035	05/02/1999	Bristol-Myers Squibb		
		WO 03/030902	04/14/2003	Tularik, Inc.		
		WO 03/006438	01/23/2003	Schering Akt.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/632,888
		Filing Date	August 1, 2003
		First Named Inventor	Bentzien, J. et al
		Group Art Unit	to be assigned
		Examiner Name	to be assigned
Sheet	2	of	2
		Attorney Docket Number	9/254

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published	T ²
		FANG, J. et al; 2-Aminobenzimidazoles as Neuropeptide Y Y5 Antagonists: Solution Phase Synthesis and Structure Relationships, ACS National Meeting, Chicago, IL, August 26, 2001	
		LINN, J., et al; Benzimidazole Neuropeptide Y Y5 Antagonists: Rapid SAR Development Using a Solid-Phase Approach, ACS National Meeting, Chicago, IL August 26, 2001	
		HEYER, D. et al; Discovery of a Novel Series of Benzimidazole-based Neuropeptide Y Y5 Antagonists from a 7-TM Targeted Chemical Library, ACS National Meeting, Chicago, IL August 26, 2001	
		AKWABI-AMEYAW, A. et al; Synthesis and SAR of Substituted 5 Acylamino Benzimidazoles as Potent Neuropeptide Y Y5 Antagonist, - ACS National Meeting, Chicago, IL, August 26 2001	
		KONG, D. et al; Chemical Components of Viscum Coloratum V. Chinese Journal of Pharmaceuticals, 1989, 20(3), pp. 110-115	
		Abstracts- American Chemical Society-Division of Medicinal Chemistry - 222nd ACS National Meeting, Chicago, IL - August 26-30, 2001	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.